TFF Pharmaceuticals, Inc - נכסים נקיים למניה בודדת TFFP

TFF Pharmaceuticals management is transparently liquidating the business and selling off patents due to a lack of funds. The specific nature of the product isolates the company from macroeconomic trends, turning its innovations into a defensive asset. The estimated book value per share demonstrates the actual asset base without speculation, where 0.90 forms the current metric indicator. The firm develops inhalation forms, relying on licenses and successful trials in the absence of regular sales.

Supply chain optimization through the outsourcing of inhalation development to external laboratories reduces capital expenditures for TFF Pharmaceuticals (TFFP), directly impacting its equity structure. This book value per ordinary share demonstrates the residual value of net assets per security, allowing investors to assess the business's actual fundamental base and the risks of impairment in the absence of operational cash flow.